% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • rojospan rojospan Nov 18, 2012 1:05 AM Flag

    VRTX starts VX 135+ Ribavirin phase II combination trial


    12 week oral drug in 2 different doses and follow up SVR 4, 12 and 24 i.e total 36 week ( 6 months duration). Study is expected to finish in 12/2013. VRTX is definately putting a good effort.
    ABT is pouring money into trials and I think ABT will defeat GILD in all oral race, both in timings and efficacy.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Soon to follow is announcement of initiation of combination trials with VX 135 with GSK's and JNJ's drugs, and VX 135 with Vertex's other hep C assets (telaprevir and VX 222), and more importantly the initiation in early 2013 of Phase 3 809/770 trials, and initiation of clinical trials of VX 509 in other inflammatory diseases. Of course VX 661/770 trial results should be a major catalyst as well in the first half of 2013. The potential for VX 787 will hopefully be revealed around the next two investor conferences in the coming weeks.

      Sentiment: Strong Buy

75.84-2.87(-3.65%)Oct 27 4:00 PMEDT